Anondita Medicare

Anondita Medicare was declared the L1 bidder by the Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, for a Schedule 1 tender to supply 8,00,62,000 condoms for the family-planning programme. The tender covered free supply and was conducted in August 2026. Government institutional business accounted for roughly half of Anondita's FY26 revenue, and its Cobra own-brand products accounted for roughly the other half. The company had annual capacity of 869m pieces across 15 lines and recorded 80.7% utilisation in FY26.

Powered by Tijori

Anondita Medicare submitted a Letter of Offer for up to 9.58 lakh fully paid-up shares at ₹950 each, seeking ₹91.01 crore through a rights issue in the ratio of 97 shares for every 1,831 held on September 2, 2026. The issue was scheduled to open on September 9 and close on September 22, with allotment and listing slated for September 23 and September 25 respectively. Net proceeds of ₹85.55 crore, after estimated issue expenses of ₹5.46 crore, were allocated to ₹50 crore of machinery for a proposed latex and non-latex female-condom facility, ₹25.75 crore of working capital and ₹9.80 crore for general corporate purposes. The promoters said they would not subscribe to their entitlements and would renounce them in favour of the public at large. The company also reported export orders of about ₹48.50 crore from customers in South Africa during the current financial year, with deliveries due by September 2026. Anondita manufactures condoms under the Cobra brand, reported FY26 revenue of ₹111.69 crore and had installed annual capacity of 869 million pieces.

Powered by Tijori

Anondita Medicare’s board approved a rights issue of 958,000 fully paid equity shares at ₹950 each, with proceeds of ₹91.01 crore assuming full subscription. Eligible shareholders will receive 97 shares for every 1,831 held, based on a September 2 record date, and the issue is scheduled to open on September 9 and close on September 22, 2026. The issue followed an in-principle approval for a rights issue of up to ₹109.78 crore on August 26. The company’s August 2025 IPO had allocated ₹6 crore to capital expenditure and ₹35 crore to working capital, while FY25 revenue was ₹60.52 crore.

Powered by Tijori

Anondita Medicare received in-principle approval from the National Stock Exchange for a proposed rights issue of fully paid equity shares aggregating up to ₹109.782 crore. The shares would have a face value of ₹10 each and be offered to eligible shareholders, subject to applicable laws and further statutory approvals. The NSE letter did not specify the number of shares, issue price or rights entitlement ratio. The company completed its IPO on NSE Emerge in August 2025. It manufactures condoms under the COBRA brand, has installed capacity of 562 million units a year and reported standalone FY25 revenue of ₹60.52 crore.

Powered by Tijori

June 16 (Reuters) - Anondita Medicare Ltd ANON.NS:

• ANONDITA MEDICARE - RECEIVES ORDER WORTH 29.2 MILLION RUPEES FROM CENTRAL MEDICAL SERVICES SOCIETY

Source text: ID:nNSE9Q8kLc

Further company coverage: ANON.NS

(([email protected];;))

April 29 (Reuters) - Anondita Medicare Ltd ANON.NS:

• ANONDITA MEDICARE - QUALIFIED AS VENDOR BY LOCAL ENTITIES IN SOUTH AFRICA

Source text: ID:nNSE9JrvmK

Further company coverage: ANON.NS

(([email protected];))